Sumit R. Majumdar, MD, MPH; Brian H. Rowe, MD, MSc; Deb Folk, RN†; Jeffrey A. Johnson, PhD; Brian H. Holroyd, MD; Donald W. Morrish, MD; Walter P. Maksymowych, MD; Ivan P. Steiner, MD; Charles H. Harley, MD; Brian J. Wirzba, MD; David A. Hanley, MD; Sandra Blitz, MSc; Anthony S. Russell, MD
Acknowledgment: The authors dedicate this work to the memory of Deb Folk, RN, our project coordinator, who was not able to see the final study results published. Without her dedication, enthusiasm, and tireless efforts on our behalf, this study would not have been possible. The authors also thank the Orthopedic Plaster Room Technicians at the University of Alberta Hospital and the Royal Alexandra Hospital for their time and effort in carrying out the study; the Epidemiology Coordinating and Research (EPICORE) Centre of the University of Alberta for providing services related to trial coordination and data management; and the expertise and efforts of our independent data monitoring and safety committee (Dr. Ross Tsuyuki, chairman).
Grant Support: By the Medical Services Budget Innovation Fund (Alberta Medical Association and Alberta Health and Wellness) and the Alberta Heritage Foundation for Medical Research. Drs. Majumdar and Johnson are Population Health Investigators and Dr. Maksymowych is a Senior Scholar of the Alberta Heritage Foundation for Medical Research; Dr. Majumdar is a New Investigator of the Canadian Institutes of Health Research; and Drs. Rowe and Johnson hold Canada Research Chairs.
Potential Financial Conflicts of Interest:Consultancies, Honoraria, Grants Received, Member of Speakers' Bureau: D.A. Hanley (Merck Frosst Canada, NPS Pharmaceuticals, Eli Lilly Canada, Procter and Gamble Canada, Aventis, Novartis, Roche, Pfizer, Wyeth, Dairy Farmers of Canada).
Requests for Single Reprints: Sumit R. Majumdar, MD, MPH, Department of Medicine, University of Alberta, 2E3.07 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta T6G 2B7, Canada; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Majumdar, Maksymowych, Morrish, Harley, Wirzba, and Russell: Department of Medicine, University of Alberta, 2E3.07 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta T6G 2B7, Canada.
Drs. Rowe, Holroyd, and Steiner and Ms. Blitz: Division of Emergency Medicine, University of Alberta, 1G1.43 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440-112th Street, Edmonton, Alberta T6G 2B7, Canada.
Dr. Johnson: Institute of Health Economics, #1200, 10405 Jasper Avenue, Edmonton, Alberta T5J 3N4, Canada.
Dr. Hanley: Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.
Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, et al. A Controlled Trial To Increase Detection and Treatment of Osteoporosis in Older Patients with a Wrist Fracture. Ann Intern Med. 2004;141:366-373. doi: 10.7326/0003-4819-141-5-200409070-00011
Download citation file:
Published: Ann Intern Med. 2004;141(5):366-373.
Many patients who sustain fragility fractures do not receive subsequent testing and treatment for osteoporosis.
This study shows that faxed reminders to physicians, treatment guidelines endorsed by opinion leaders, and patient education about osteoporosis can increase the testing and therapy for osteoporosis among patients who present to an emergency department with wrist fracture.
This study did not randomly assign persons to the intervention group and did not examine improvements in bone density or repeated fractures.
Osteoporosis, a chronic and progressive condition that leads to decreased bone mass and skeletal fragility, may result in fractures, disability, pain, deformity, and even death (1-3). The condition is common, affecting an estimated 1.4 million Canadians and 10 million Americans (1, 2). These figures represent 25% of women and 12% of men older than 50 years of age (1, 2). In the United States, the annual cost of treating osteoporosis and its sequelae has been estimated at $13.8 billion (2), compared with $7.5 billion for congestive heart failure and $6.2 billion for asthma (3). Without better preventive strategies, the rate of osteoporotic fractures is expected to double over the next 15 years (4).
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Metabolic Bone Disorders, Prevention/Screening.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only